Navigation Links
Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery
Date:9/1/2008

ption, then patients were placed in one of two parallel registries for PCI or CABG.

SYNTAX is breaking new ground by scientifically defining a new measure for anatomical complexity - the SYNTAX Score - which seeks to provide guidance to physicians on optimal treatment options for this high-risk group of patients. The SYNTAX Score characterizes vasculature based on lesion frequency, complexity and location, relying on data from the SYNTAX trial as well as information collected through other sources.

The safety and effectiveness of the TAXUS Express2 Stent System has not been established in patients with left main or three-vessel disease.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, regulatory approvals, competitive offerings and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together w
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioStorage Technologies Serves as Repository for Landmark Study of Coronary Artery Disease
2. Asthma Uncontrolled in More Than 40 Percent of Adults With the Disease, New Landmark Survey Shows
3. Presentation of Landmark Clinical Trial Evaluating Endoscopic Treatment for Pre-cancerous Condition of Esophagus
4. Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord
5. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
6. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
7. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
8. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
9. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
10. A Statement From Larry Corey, MD, of the HIV Vaccine Trials Network Regarding the New HIV Infection Statistics Released Today by the Centers for Disease Control
11. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/7/2009)... Nov. 7, Research projects in the ...arks this evening, as Tim Kunisky of Livingston, N...en of Audubon, PA received the highest honors at t...ion in Math, Science & Technology, the nation,... http://www.newscom.com/cgi-bin/prnh/20070904/SIE...
(Date:11/6/2009)...Nov. 6 Helix BioPharma C...announced that John Docherty, president and chief ... Ford,s 6th annual Investor Summit on November 10,...City. Mr. Docherty will provide an overview of th...-DOS47 and Topical Interferon Alpha-2b. The slide...
(Date:11/6/2009)..., Nov. 6 ,, 3Q09 C...f Qutenza(TM) E.U. Marketing Authorization to Aste...s in commercial readiness activities Expanded man... Marketing; and Director, Commercial Operations A...and Audit Committee chairman , Upcoming 200...
(Date:11/6/2009)...Nov. 6 Intarcia Therapeutics, Inc.... (DUROS® continuous delivery of exenatide) pr...Ninth Annual Diabetes Technology Meeting in San Fr...cgi-bin/prnh/20050301/SFTU126LOGO ) ,, Contin...50 Lowers Plasma Glucose, HbA1c and Reduces Weight...
Breaking Biology Technology:Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 2Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 3Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 4Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 5Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 6Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5
... on the past, present and future of Dept. of Comme...up to WTNs interview with Nettles in March 2003....x to 12 months, what Dept. of Commerce initiatives...y Nettles: I had a meeting with Gov. Doyle a coup... Commerces activities: where we are and what were ...
...arolina and Los Angeles become havens for entrepre...of angel investors shared their most effective pra... Milwaukee . , ,Their techniques included educatio...ord, said Monica Doss, president of the Council f...rolinas Research Triangle Park. Entrepreneurs and ...
...ence got off to a dynamic start on Tuesday morning... a hundred entrepreneurs and industry representati...ccess. The entrepreneurial boot camp was designed... providing a loose outline for success from a pane... focus on what were doing here, said Ken Wanek, fo...
Other Biology Technology:WTN exclusive interview with Commerce Secretary Cory Nettles (part 2) 2WTN exclusive interview with Commerce Secretary Cory Nettles (part 2) 3WTN exclusive interview with Commerce Secretary Cory Nettles (part 2) 4WTN exclusive interview with Commerce Secretary Cory Nettles (part 2) 5Experts share advice for Wisconsin entrepreneur programs 2Experts share advice for Wisconsin entrepreneur programs 3Experts share advice for Wisconsin entrepreneur programs 4Entrepreneurs get crash course for building a successful company 2Entrepreneurs get crash course for building a successful company 3
(Date:11/5/2009)... University have developed synthetic molecules cap...V and HIV-infected cells, as well as to prostate c...he Journal of the American Chemical Society , cou...diseases. , The molecules called "antibody-rec...ody-recruiting molecule targeting prostate cancer"...
(Date:11/4/2009)...ildhood obesity in the United States is reaching e...advertising on daytime and prime time television d...ions about the role television plays in obesity, a...nal of Nutrition Education and Behavior examines ...large contributor to the problem. , Researchers ...
(Date:11/4/2009)...ire-FirstCall/ -- Quest Diagnostics Incorporated (...nostic testing, information and services, announce...009, income from continuing operations rose to $19...illion, or $0.81 per diluted share, for the third ...re reduced by a $0.03 per share charge associated ...
Breaking Biology News(10 mins):New synthetic molecules trigger immune response to HIV and prostate cancer 2TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Quest Diagnostics Reports Strong Performance in Third Quarter 2009 2Quest Diagnostics Reports Strong Performance in Third Quarter 2009 3Quest Diagnostics Reports Strong Performance in Third Quarter 2009 4Quest Diagnostics Reports Strong Performance in Third Quarter 2009 5Quest Diagnostics Reports Strong Performance in Third Quarter 2009 6Quest Diagnostics Reports Strong Performance in Third Quarter 2009 7Quest Diagnostics Reports Strong Performance in Third Quarter 2009 8Quest Diagnostics Reports Strong Performance in Third Quarter 2009 9Quest Diagnostics Reports Strong Performance in Third Quarter 2009 10Quest Diagnostics Reports Strong Performance in Third Quarter 2009 11Quest Diagnostics Reports Strong Performance in Third Quarter 2009 12Quest Diagnostics Reports Strong Performance in Third Quarter 2009 13Quest Diagnostics Reports Strong Performance in Third Quarter 2009 14Quest Diagnostics Reports Strong Performance in Third Quarter 2009 15Quest Diagnostics Reports Strong Performance in Third Quarter 2009 16Quest Diagnostics Reports Strong Performance in Third Quarter 2009 17New Laser Treatment for Cellulite Helps Fight the Battle 53029 1New Laser Treatment for Cellulite Helps Fight the Battle 53029 2New Laser Treatment for Cellulite Helps Fight the Battle 53029 3Natural Healers Discusses How Personal Trainer Certification May Be Changing in Some States 53024 1Natural Healers Discusses How Personal Trainer Certification May Be Changing in Some States 53024 2Natural Healers Discusses How Personal Trainer Certification May Be Changing in Some States 53024 3Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe 53019 1Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe 53019 2Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe 53019 3Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe 53019 4
... has been one of the great mysteries in plant scie...plant growth hormone auxin exists. They,ve known o...ment since the 1930s. But only now do scientists k... University Bloomington biologists Mark Estelle, N...IR1 as the protein that, with auxin, influences ho...
...TH great fanfare a South Korean team announced las...ate human embryonic stem cells that were genetical... could already be obsolete. Another team headed by...tute, based in Chicago, claims to have produced pa...ng to therapeutic cloning. "It would be a much bet...
...ilent Technologies Inc. (NYSE: A) and Proteome Sys...today announced they have signed a marketing agree...the analysis of glycoproteins, molecules that are ... cancer, influenza and arthritis. Under the agreem...are, a comprehensive platform for the mass spectro...
Other Biology News:At long last, scientists figure out how plants grow 2Double triumph in stem cell quest 2Double triumph in stem cell quest 3Double triumph in stem cell quest 4Integration of Agilent's MS technology, Proteome Systems' software to help scientists in proteomics research 2
Mouse Anti-Human p53, wild & mutant, aa 19-26 Monoclonal Antibody, Unconjugated, Clone DO-7 from CHEMICON
Tube-O-DIALYZER Floats, Floats, Small from CHEMICON
Anti-Feline Rhinotracheitis Virus Monoclonal Antibody, Unconjugated from ViroStat Inc.
Anti-Ezrin / Radixin / Moesin Antibody, Unconjugated from Cell Signaling Technology
Biology Products: